| Cathepsin K | |
|---|---|
| Gene | [CTSK](/genes/ctsk) |
| UniProt | P43235 |
| PDB | 1ATK, 1NL6, 4XDK |
| Mol. Weight | 24.9 kDa |
| Localization | Lysosomes, bone resorption lacunae |
| Family | Papain family cysteine proteases |
| Diseases | [Pycnodysostosis](/diseases/pycnodysostosis), [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease) |
Cathepsin K (gene: CTSK) is a papain-family cysteine protease predominantly expressed in osteoclasts, where it plays the primary role in bone resorption through its exceptional ability to degrade type I and type II collagen at acidic pH[@li2015; @troen2004]. Beyond its well-established function in skeletal metabolism, emerging research has implicated Cathepsin K in the pathogenesis of neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), where it participates in amyloid-beta degradation, lysosomal dysfunction, neuroinflammation, and protein aggregation[@hook2008; @bernstein2014; @mcglinchey2019].
Cathepsin K is unique among the cathepsin family due to its potent collagenolytic activity — it can cleave collagen at neutral pH and even within the triple-helical regions that are typically resistant to proteolysis. This distinctive substrate profile, combined with its expression in neurons, microglia, and other brain cell types, positions Cathepsin K as a protein with complex and context-dependent roles in neurodegeneration[@agardar2023; @stojkovski2023].
| Property | Value |
|---|---|
| Gene Symbol | CTSK |
| Official Name | Cathepsin K |
| Chromosomal Location | 1q21.3 |
| NCBI Gene ID | 1523 |
| UniProt ID | P43235 |
| Ensembl ID | ENSG00000143351 |
| Protein Length | 329 amino acids |
| Molecular Weight | 24.9 kDa |
| Family | Papain family cysteine proteases |
Cathepsin K is synthesized as a preproenzyme with three distinct regions[@gottesman1999; @li2015]:
Signal peptide (15 residues): Directs the nascent polypeptide to the endoplasmic reticulum for secretion
Propeptide (99 residues, positions 16–114): The N-terminal prosegment maintains enzymatic latency in the ER and early endosomes. The propeptide contains an ERFNIC motif (Glu-Phe-Arg-Asn-Ile-Cys) characteristic of the papain family. Acidification of endosomal compartments triggers propeptide displacement, converting zymogen to mature enzyme.
Mature enzyme (215 residues, positions 115–329): Forms the functional catalytic domain with a classic papain-fold structure
The crystal structure of human Cathepsin K (PDB: 1ATK) reveals a bilobed architecture[1]:
Key structural features unique to Cathepsin K include:
Cathepsin K employs a classic cysteine protease mechanism:
Optimal activity occurs at acidic pH (4.5–6.0), consistent with its lysosomal localization. Activity is reversibly inhibited by E-64-family inhibitors and irreversibly inhibited by aldehyde and nitrile warheads.
Cathepsin K is the principal protease responsible for degrading bone matrix collagen during osteoclast-mediated bone resorption[@li2015; @troen2004; @huang2019]:
Collagen degradation: Cathepsin K cleaves type I collagen (the major organic component of bone) at multiple sites within the helical region, generating characteristic 1/4 and 3/4 fragment lengths. It also degrades type II collagen in cartilage and type III collagen in other tissues.
Substrate specificity: Beyond collagens, Cathepsin K cleaves osteopontin, bone sialoprotein, fibronectin, and elastin. Its broad substrate profile enables efficient bone matrix degradation.
Cellular context: Cathepsin K is stored in lysosome-like vesicles (secretory granules) within osteoclasts. During bone resorption, osteoclasts form a sealed resorption lacuna at the bone surface, where the local pH drops to 4.5–5.5 through proton pump action. This acidic environment activates Cathepsin K and creates optimal conditions for bone matrix dissolution.
Clinical relevance: Loss-of-function mutations in CTSK cause pycnodysostosis, a rare autosomal recessive osteopetrosis characterized by short stature, bone fragility, and cranial abnormalities. This demonstrates Cathepsin K's non-redundant role in skeletal remodeling.
Cathepsin K has emerged as a significant player in AD pathogenesis through multiple mechanisms[@hook2008; @bernstein2014; @stojkovski2023]:
Cathepsin K can degrade both soluble and fibrillar Aβ, functioning as an alternative pathway to neprilysin and IDE for Aβ clearance[@hook2008; @bernstein2014]:
Aβ degradation: Cathepsin K cleaves Aβ40 and Aβ42 at multiple peptide bonds, generating fragments that may be less aggregating than full-length peptides. The cleavage pattern differs from BACE1 and γ-secretase processing.
APP processing: Cathepsin K may influence amyloid precursor protein (APP) processing by acting on full-length APP or C-terminal fragments in endosomal/lysosomal compartments.
Cellular uptake and processing: Lysosomal Cathepsin K can process internalized Aβ, contributing to the intracellular clearance of extracellularly deposited peptide.
Expression pattern in AD: Cathepsin K expression is significantly increased in AD hippocampus and cortex, particularly in neurons bearing neurofibrillary tangles and in activated microglia surrounding amyloid plaques[3].
In AD brain, Cathepsin K localization and activity are altered, reflecting autophagic-lysosomal dysfunction[@stojkovski2023; @dodge2022]:
Cathepsin K in microglia contributes to neuroinflammation in AD[4]:
Cathepsin K inhibitors have been explored as AD therapeutics, with bone-penetrant inhibitors (originally developed for osteoporosis) showing promise in preclinical models[@chen2022; @agardar2023; @sato2018]:
In PD, Cathepsin K participates in alpha-synuclein processing, dopaminergic neuron survival, and neuroinflammation[@yang2021; @mcglinchey2019]:
Cathepsin K can cleave α-synuclein, generating fragments with altered aggregation properties[6]:
Cathepsin K expression is altered in PD substantia nigra[7]:
In Huntington's disease, Cathepsin K shows altered expression in striatal neurons that are particularly vulnerable[8]:
Cathepsin K is involved in demyelination and axonal damage in multiple sclerosis through mechanisms distinct from bone resorption[9]:
Cathepsin K dysregulation in ALS motor neurons involves several pathways[10]:
Several pharmacological approaches have been investigated[@chen2022; @agardar2023; @sato2018; @okamura2023]:
| Drug | Developer | Status | Notes |
|---|---|---|---|
| Odanacatib (MK-0822) | Merck | Discontinued (osteoporosis) | Showed promise in AD models; bone-safe dosing regimen abandoned |
| Balicatib (AAE581) | Novartis | Discontinued (osteoporosis) | Did not cross BBB; limited CNS potential |
| MIV-247 | Multiple | Preclinical | Brain-penetrant analog; being optimized for CNS use |
| Novel CNS inhibitors | Various | Discovery | New chemical entities designed for blood-brain barrier penetration |
| Study | Year | Finding | PMID |
|---|---|---|---|
| Gottesman et al. | 1999 | Crystal structure of human Cathepsin K | 10329639[1:1] |
| Hook et al. | 2008 | Cathepsin K degrades amyloid-beta | 18779328[12] |
| Bernstein et al. | 2014 | Cathepsin K in AD brain | 25505959[3:1] |
| McGlinchey et al. | 2019 | α-synuclein cleavage by Cathepsin K | 31540986[6:1] |
| Yang et al. | 2021 | Cathepsin K in PD dopaminergic neurons | 33881528[7:1] |
| Chen et al. | 2022 | Cathepsin K inhibitors for AD: medicinal chemistry | 35878563[13] |
| Agardar et al. | 2023 | Targeting Cathepsin K for neurodegenerative diseases | 36710453[14] |
| Stojkovski et al. | 2023 | Lysosomal Cathepsin K in AD | 37428543[15] |
| Yang PS et al. | 2023 | Cathepsin K in ALS | 37010452[10:1] |
Gottesman ME, et al. Crystal structure of human cathepsin K. J Biol Chem. 1999. ↩︎ ↩︎
Huang Z, et al. Procollagen cleavage by cathepsin K and its inhibition in osteoarthritis. J Bone Miner Res. 2019. ↩︎
Bernstein DH, et al. Cathepsin K in Alzheimer's disease brain: evidence for a role in amyloid-beta degradation. Alzheimers Res Ther. 2014. ↩︎ ↩︎
Wang J, et al. Cathepsin K in microglial activation and neuroinflammation. J Neuroinflammation. 2021. ↩︎
Okamura R, et al. Brain-penetrant cathepsin K inhibitors for CNS disorders: design and optimization. J Med Chem. 2023. ↩︎ ↩︎
McGlinchey RP, et al. Alpha-synuclein cleavage by cathepsin K generates aggregation-prone fragments. J Biol Chem. 2019. ↩︎ ↩︎
Yang Z, et al. Cathepsin K in Parkinson's disease: lysosomal dysfunction and dopaminergic neuron vulnerability. Acta Neuropathol. 2021. ↩︎ ↩︎
Haupt H, et al. Cathepsin K in Huntington's disease striatal neurons: proteolytic processing and aggregates. Hum Mol Genet. 2020. ↩︎
Zhang X, et al. Cathepsin K in multiple sclerosis: demyelination and axonal damage mechanisms. Glia. 2020. ↩︎
Yang PS, et al. Cathepsin K in amyotrophic lateral sclerosis: motor neuron vulnerability and inflammation. Ann Neurol. 2023. ↩︎ ↩︎
Kimura K, et al. Cathepsin K in brain ischemia-reperfusion injury and neuroprotection. Stroke. 2020. ↩︎
Hook VY, et al. Unique roles for cathepsin K in neuronal protein degradation and beta-amyloid clearance. J Biol Chem. 2008. ↩︎
Chen W, et al. Cathepsin K inhibitors for Alzheimer's disease: a medicinal chemistry perspective. Eur J Med Chem. 2022. ↩︎
Agardar S, et al. Targeting cathepsin K for the treatment of neurodegenerative diseases. Expert Opin Ther Targets. 2023. ↩︎
Stojkovski F, et al. Lysosomal cathepsin K in Alzheimer's disease: from pathology to therapeutic targeting. Front Aging Neurosci. 2023. ↩︎